Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Extavia

- PMLiVE

Novartis makes case for gene therapy Zolgensma in SMA

New data revealed ahead of FDA review

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Biogen’s Spinraza overpriced, says ICER

Cost watchdog warns high price puts pressure on US health system

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

- PMLiVE

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

- PMLiVE

NICE recommends MSD’s diabetes drug Steglatro

MSD offering lowest price to win share of SGLT-2 inhibitor market

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

Downloadable Pack: Understanding Multiple Sclerosis

Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.

Blue Latitude Health

Six factors that drive a multiple sclerosis patient’s choice of disease-modifying therapy

MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links